Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618112 | 1.00 | TACR1 (0.67) | TACR1CTSL | |
| SCHEMBL16617948 | 0.94 | TACR1 (0.67) | TACR1CTSL | |
| SCHEMBL16617278 | 0.94 | TACR1 (0.64) | TACR1CTSL | |
| SCHEMBL16618163 | 0.93 | TACR1 (0.67) | TACR1 | |
| SCHEMBL16618165 | 0.93 | TACR1 (0.67) | TACR1 | |
| SCHEMBL16617689 | 0.93 | MEN1 (0.63) | TACR1CTSL | |
| SCHEMBL16617078 | 0.93 | TACR1 (0.69) | TACR1CTSL | |
| SCHEMBL16617101 | 0.93 | MEN1 (0.66) | TACR1CTSL | |
| SCHEMBL16617625 | 0.93 | TACR1 (0.75) | TACR1CTSL | |
| SCHEMBL16617103 | 0.93 | MEN1 (0.66) | TACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4196122-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-9593144-B2 | FPR1 antagonist derivatives and use thereof | CHANG GUNG UNIVERSITY (TW) | 2017-03-14 | — | — | US | disclosed |
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | TACR1 84/4885CTSL 957/4885 |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | TACR1 84/4885CTSL 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.